Graft Versus Host Disease Cgvhd clinical trials

Explore recruiting graft versus host disease cgvhd clinical trials.

Recruiting graft versus host disease cgvhd studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Graft Versus Host Disease Cgvhd trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)

France, Italy, Spain, Netherlands, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Systemic Therapy.

Spain, France, Italy, Greece, Belgium, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A multiCenter phase I study of aUtologous CD19 CAR T cElls for therapy refractory chronic GvHD (CURE-cGvHD)

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Study of Q702 in Subjects with Relapsed or Refractory Chronic Graft-versus-Host Disease (cGVHD)

Spain

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

A Randomised, Open label, Multicentre, Phase 3 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid refractory Acute Graft versus host Disease After Allogeneic Haematopoietic Stem Cell Transplantation (IDUNN Trial)

Poland, Spain, France, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomised, Open label, Controlled, Multicentre, Phase 2 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Paediatric Participants with Steroid refractory Acute Graft versus host Disease After Allogeneic Stem Cell Transplantation (BALDER Trial)

France, Spain, Germany, Poland, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Graft Versus Host Disease Cgvhd trials by city

Graft Versus Host Disease Cgvhd in Toronto Graft Versus Host Disease Cgvhd in Vancouver Graft Versus Host Disease Cgvhd in Montreal Graft Versus Host Disease Cgvhd in Calgary Graft Versus Host Disease Cgvhd in Edmonton Graft Versus Host Disease Cgvhd in Ottawa Graft Versus Host Disease Cgvhd in Winnipeg Graft Versus Host Disease Cgvhd in Quebec City Graft Versus Host Disease Cgvhd in Hamilton Graft Versus Host Disease Cgvhd in Kitchener Graft Versus Host Disease Cgvhd in London Graft Versus Host Disease Cgvhd in Halifax Graft Versus Host Disease Cgvhd in New York Graft Versus Host Disease Cgvhd in Los Angeles Graft Versus Host Disease Cgvhd in Chicago Graft Versus Host Disease Cgvhd in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease